6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-04-22), NovoCure's 6-1 Month Momentum % is 18.81%.
The industry rank for NovoCure's 6-1 Month Momentum % or its related term are showing as below:
NVCR's 6-1 Month Momentum % is ranked better than 83.06% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: -6.42
vs NVCR: 18.81
Competitive Comparison of NovoCure's 6-1 Month Momentum %
For the Medical Devices subindustry, NovoCure's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure's 6-1 Month Momentum % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where NovoCure's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
NovoCure 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of NovoCure's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVCR has been successfully added to your